OpportunityTitle: Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.   see NOFO for eligibility details
Description: The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clinical outcome measures) previously assessed in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) project. The CTDPACC will support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial utilizing a Phase 2 ready compound or compounds.
GrantorContactEmailDescription: See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
GrantorContactText: NIH Grants Information&lt;br/&gt;grantsinfo@nih.gov